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Abstract
Reduced nutritional state is associated with unfavourable outcomes
and a lower quality of life in patients with malignancies. Patients with
J. Arends1
G. Zuercher2active tumour disease frequently have insufficient food intake. The
A. Dossett1resting energy expenditure in cancer patients can be increased, de-
R. Fietkau3creased, or remain unchanged compared to predicted values. Tumours
may result in varying degrees of systemic pro-inflammatory processes M. Hug4
with secondary effects on all significantmetabolic pathways. Therapeutic
I. Schmid5objectives are to stabilise nutritional state with oral/enteral nutrition
E. Shang6and parenteral nutrition (PN) and thus to prevent or reduce progressive
weight loss. The maintenance or improvement of quality of life, and the A. Zander7
increase in the effectiveness and a reduction in the side-effects of
Working group for
developing the
antitumor therapy are further objectives. Indications for PN in tumour
patients are essentially identical to those in patients with benign ill-
nesses, with preference given to oral or enteral nutrition when feasible. guidelines for
A combined nutritional concept is preferred if oral or enteral nutrition parenteral nutrition of
are possible but not sufficient. There are generally no accepted stand- The Germanards for ideal energy and nutrient intakes in oncological patients, par-
Association for
Nutritional Medicine
ticularly when exclusive artificial nutrition is administered. The use of
PN as a general accompaniment to radiotherapy or chemotherapy is
not indicated, but PN is indicated in chronic severe radiogenic enteritis
or after allogenic transplantation with pronounced mucositis or GvH- 1 Dept. of Medical Oncology,
Tumour Biology Center,related gastrointestinal damage for prolonged periods, with particular
attention to increased risk of bleeding and infection. No PN is necessary
in the terminal phase.
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Ein reduzierter Ernährungszustand ist mit einer eingeschränkten Pro-
gnose und verminderter Lebensqualität assoziiert. Patientenmit aktiver
3 Depts. Paediatric Surgery and
Radiation Therapy, University
of Rostock, Germany
4 Pharmacy, University Hospital
Freiburg, GermanyTumorerkrankung haben häufig eine unzureichendeNährstoffaufnahme.
Der Ruhe-Energieumsatz kann im Vergleich zumErwartungswert unver-
5 Dept. Metabolic Diseases &
Nutritional Medicine, Dr. von
ändert, gesteigert oder vermindert sein. Bei manifesten Tumorerkran-
kungen kommt es in unterschiedlichem Ausmaß zu systemischen pro-
Hauner Children's Hospital,inflammatorischen Prozessen mit sekundären Auswirkungen auf alle University of Munich,
Germanywesentlichen Stoffwechselwege. Durch eine parenterale Ernährung (PE)
soll der Ernährungszustand stabilisiert und ein fortschreitender Gewichts-
6 Dept Surgery, University
Hospital of Mannheim,
Germany
verlust verhindert oder reduziert werden. Weitere Ziele sind der Erhalt
oder eine Verbesserung der Lebensqualität und eine Erhöhung der Ef-
fektivität sowie eine Reduktion von Nebenwirkungen der antitumoralen
7 Dept. of Oncology and
Haematology, University of
Hamburg, Germany
Therapie. Prinzipiell sind die Indikationen für eine PE bei Tumorpatienten
identisch mit den Indikationen bei Patienten mit gutartigen Erkrankun-
gen, wobei bei Tumorpatienten eine orale oder enterale Nahrungszufuhr
immer vor einer PE eingesetzt werden sollte. Bei möglicher oraler oder
enteraler Zufuhr ergibt sich ein kombiniertes Ernährungskonzept. Für
1/14GMS German Medical Science 2009, Vol. 7, ISSN 1612-3174
Review ArticleOPEN ACCESSSpecial Issue
die optimale Energie- und Nährstoffzufuhr onkologischer Patienten,
besonders für die ausschließliche künstliche Ernährung, gibt es keine
allgemein akzeptierten Standards. Der generelle Einsatz einer PE be-
gleitend zum Strahlentherapieverfahren oder zur Chemotherapie ist
nicht sinnvoll, ist jedoch indiziert bei chronischer schwerer radiogener
Enteritis oder nach allogener Transplantationwegen einer ausgeprägten
Mukositis und GvH-bedingten Gastrointestinalschäden mit besonderer
Rücksicht auf das erhöhte Blutungs- und Infektionsrisiko. In der Sterbe-
phase ist keine PE erforderlich.
Schlüsselwörter: Tumor, Radiotherapie, Chemotherapie,
Stammzelltransplantation
The nutritional state influences the
clinical outcome
• Reduced nutritional state is associated with unfavour-
able outcomes and a lower quality of life in patients
with malignancies (IIa).
Commentary
Adult tumour patients who have lost weight or are mal-
nourished show an unfavorable outcome in longitudinal
studies. The response to antitumor treatment is de-
creasedwhile treatment-associated side effects aremore
frequent; physical performance and quality of life are
compromised; overall survival is significantly shorter than
in patients without weight loss [1], [2], [3], [4], [5], [6],
[7], [8], [9], [10], [11]. Cachexia is the most common
cause of death in tumour patients other than sepsis [12].
In a recent study body nitrogen content was found to be
the strongest predictor for protection against bone mar-
row toxicity during chemotherapy in patients with breast
cancer [13].
The effect of malnutrition on the rate of cure in children
with cancer is controversial. While a significantly lower
rate of healing is reported in malnourished patients (Ib)
[14], [15], [16], [17], [18], there appears to be no influ-
ence on patients’ survival (IIa) [19], [20], [21], [22]. These
differences depend on the various definitions of malnu-
trition, the type and extent of the tumour, tumour therapy,
supportive measures and the socio-economic status of
the family. Malnutrition is known to decrease immuno-
competence (IIa) [23], [24], decrease the tolerance to
chemotherapy (IIa) [25] and increase the rate of infection
(IIa) [26], [27]. Information on organ dysfunction as a
result of malnutrition in children with cancer is scarce. In
malnourished children there is an increased risk of cardi-
omyopathy after the administration of anthracyclines (IV)
[28].
Influence of malignancies on
energy expenditure
• Patients with active tumours frequently have insuffi-
cient food intake (II).
• The resting energy expenditure in cancer patients can
be increased, decreased, or remain unchanged in
comparison to the predicted value (II).
Commentary
Food intake is lower than the usual even in patients with
early stage tumour disease, and there is often a large
discrepancy between the actual energy and protein intake
and the calculated requirements in advanced tumour
stages [10], [29].
In approximately 25% of patients with active tumours,
resting energy expenditure (REE), asmeasured by indirect
calorimetry, is more than 10% above, and in another 25%
more than 10% below the predicted value. A prediction
as to the direction and extent of the deviation is not
possible [30], [31]. The mean value of total energy ex-
penditure in cancer patients is similar to that of a healthy
reference group [31], [32]. Studies in patients with vari-
ous tumour entities showed a normal REE in people with
stomach or colorectal carcinomas, and an increasedREE
in patients with pancreatic or bronchial carcinomas [33],
[34], [35], [36]. More detailed investigations in patients
with advanced bronchial and pancreatic carcinomas re-
vealed an increased REE coupled with diminished phys-
ical activity and a slightly lower overall energy expenditure
when compared to healthy subjects [35], [36].
Therefore, in adult patients normal energy expenditure
should be assumed if the actual resting energy expend-
iture cannot be measured in individual cases. Formulae
(i.e. Harris Benedict, cf. chapter “Energy expenditure and
energy intake” (http://www.egms.de/en/gms/2009-
7/000084.shtml)) may be used to calculate the normal
resting energy expenditure. In patients, the overall energy
requirement is also determined by physical activity and
may be estimated as 100–120% of REE (cf. chapters
“Energy expenditure and energy intake” (http://
www.egms.de/en/gms/2009-7/000084.shtml) and
“Neonatology/Paediatrics” (http://www.egms.de/en/
gms/2009-7/000074.shtml) for children’s energy ex-
penditure).
Studies have shown that children with leukaemia have
a near normal resting energy expenditure at diagnosis
and during anti-cancer treatment [24], [37], [38], [39],
[40]. Resting energy expenditure, however, is increased
in leukaemic children with large tumour mass [38], and
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Manifest tumours result in varying degrees of systemic
pro-inflammatory processes with secondary effects on all
significant metabolic pathways [42]. A large body of data
suggests that the primary reaction of the tumour-bearing
host is to release cytokines, catabolic hormones and
other regulatory peptides locally and systemically [42],
[43], [44].
The resulting systemic inflammatory reaction contributes
significantly to the loss of appetite [45], [46] and weight
[47], [48], [49], [50]. These cytokine-induced metabolic
changes prevent a recovery of body cell mass [51], and
are associated with reduced life expectancy [52] in
cachectic patients [52], [53].
Effects on carbohydrate metabolism
• Insulin resistance and increased glucose production
can often be detected in tumour patients (II).
Commentary
Impaired glucose tolerance due to insulin resistance is
common in tumour patients [54]. The plasma ratio of in-
sulin to catabolic hormones is abnormal with typical
findings of increased cortisol secretion and a decreased
insulin-cortisol ratio [44], [55]. This results in increased
glucose turnover and gluconeogenesis [43]. Concomitant
medication with high-dose glucocorticoids intensifies
these changes.
Effects on lipid metabolism
• Weight loss in cancer patients is accompanied by a
loss of lipid stores and increased serum triglycerides.
The ability to oxidise lipids is normal to increased (II).
Commentary
The reasons for changes in lipid metabolism have not yet
been clearly determined [44] although increased lipolysis
is often observed [56], [57]. Increased [57], [58], [59] or
at least normal [60], lipid oxidation is often detectable
at the same time, while glucose oxidation is compromised.
These observationsmay support the recommendation to
increase the lipids to glucose ratio when composing nu-
trition for cancer patients.
Effects on protein metabolism
• Protein expenditure is usually increased, resulting in
a loss of muscle mass and an increased production
of acute phase proteins (II).
Commentary
While the underlying processes are complex, usually in-
creases in overall body protein turnover and in proteolysis
are measured [43], [61]. The ATP consuming and ubi-
quitin-dependent proteolysis system of proteasomes is
activated at an early stage [62], [63], [64]. These changes
are triggered by inflammatory mediators and, possibly,
additional substances released by the tumour [65], [66].
Treatment aims for parenteral
nutrition (PN) in cancer patients
• PN should stabilise the nutritional state and prevent
or reduce progressive weight loss (C).
• PN should maintain or improve the quality of life (C).
• PN might increase the effectivity and reduce the side-
effects of anti-cancer therapies (C).
Commentary
After curative antitumour treatment, PN can enhance
survival chances in patients with severe gastrointestinal
defects e.g. with radiation enteritis [67]. Due to the ac-
companying non-specific inflammatory processes in pa-
tients with active cancers anabolism usually cannot be
achieved by only supplying energy and substrates [44],
[50], [51]. According to data collected on body compart-
ments, artificial nutrition results in a stabilisation of or
an increase in body weight [68], [69], [70], [71] and body
fat mass, while an improvement in lean body or muscle
mass is observed only rarely [72].
Numerous studies reported a median overall survival of
50 to 150 days [69], [70], [71], [73], [74], [75], [76],
[77], [78] when using PN in patients with advanced can-
cer and chronic small bowel defects. In the majority of
these patients weight [69], [70], [71], and parameters
to measure quality of life may be stabilized [69], [70],
[71], [75]. The rate of PN-associated infectious complica-
tions is between 0.34 and 2.68 per 1000 catheter days
[74], [76], [77], [78].
Orreval et al. reported that the provision of home PN was
perceived as a positive alternative to progressive weight
loss due to the inability to eat in a small group of patients
with advanced tumours [79].
Meta-analyses indicate that PNmay reduce postoperative
complications in malnourished, but not in normally
nourished, patients after extensive abdominal surgery
[80]. In contrast, only few studies have evaluated the in-
fluence of PN on the therapeutic effects of non-surgical
oncology. Parenteral nutrition in orally nourished patients
undergoing chemotherapymay increase body weight [68]
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(Ib), but does not improve anticancer treatment [68], [81]
(Ib). The quality of these few studies, however, is restric-
ted by the inhomogeneity of the patient groups and by
the inclusion of patients without malnutrition or patients
who were able to eat normal amounts of food [81].
Indication for parenteral nutrition
in cancer patients
Indications for PN in tumour patients are essentially
identical to those in patients with benign illnesses. Con-
sidering the limited data available in this area [82], [83],
[84], [85], [86], [87], [88] the following recommendations
are given:
• PN is indicated if oral and enteral food intake [83],
[84] provide <500 kcal per day and this is expected
to continue for >5 days, or for between 3 and 5 days
in case of severe malnutrition, or if oral and enteral
food intake reach <60% of calculated requirement and
this is expected to last for 10–14 days in adult patients
(C).
• PN should be commenced immediately when indicated,
and increased to target dosages over 2–4 days if
considered necessary (C).
• The amount of PN should supplement oral or enteral
nutrition, providing full nutritional requirements in
combination (C).
• PN in children is indicated (C):
in severe malnutrition•
in borderlinemalnutrition and high risk for malnutri-
tion through therapy, etc.
•
when oral food intake is <60% of the energy and
protein requirements and there is a high risk for
treatment-induced malnutrition, etc.
•
• PN is used in children if digestion or absorption of food
is impaired and it is expected that the patient will re-
quire nutritional therapy for at least 7 days. PN should
be commenced as soon as possible and continued
until the gastrointestinal tract is fully functioning.
Regular checks should be carried out if it is expected
that the patient will require a nutrition therapy for less
than 7 days (C).
Commentary
In tumour patients, who are not able to eat, digest or ab-
sorb foods, the nutritional state may be maintained or
improved by PN [71], [75], [89], [90], [91]. This includes
situations with severe intestinal defects caused by radi-
ation enteritis, chronic ileus, severe adhesions, short
bowel syndrome, peritoneal carcinosis or the occurrence
of chylothorax.
In 1994 Klein and Koretz analysed several prospective
randomised-controlled studies on the effects of PN re-
gimes in tumour patients, including 22 studies on peri-
operative nutrition, 18 studies using PN during the course
of chemotherapy, and 4 studies using PN during radio-
therapy [81]. They found no general advantage of PN re-
garding morbidity or mortality, but an increased rate of
infection in patients receiving chemotherapy.
Definitive conclusions on the role of PN in the three
treatment modalities, however, were not possible due to
major flaws in most studies. Most studies had included
only few subjects of heterogeneous patient groups under-
going various antitumor therapies. Individual studies were
not comparable as they had used different criteria for
initiation of artificial nutrition as well as different nutrition
regimens and different treatment durations. In addition,
patients in these studies were treated despite having a
normal, or only a slightly impaired, nutritional state [85],
[86].
PN increases tumour cell proliferation [92], [93], [94],
[95], [96], [97] and sensitivity to chemotherapy [94], [97]
in in-vitro models. In malnourished patients with gastric
cancer, concomitant administration of PN with preopera-
tive chemotherapy improved nutritional state, reduced
post-operative complications, but did not influence the
pre-operative tumour cell proliferation [97].
Using PN during tumour therapy improved the nutritional
state of children (Ib) [23], [98], [99], [100]. Several
studies indicate that chemotherapy is better tolerated
when accompanied by PN, resulting in fewer therapy
delays, dose reductions and shorter myelosuppression
(Ib) [15], [100], [101], [102], [103]. However, other data
suggest that the use of PN does not lower the incidence
of therapy-related complications (IIa) [98], [104]. In add-
ition, there is no evidence that targeted nutritinal therapy
might increase the chance of healing [105] (UICC 34).
On the contrary, PN is associated with an increased rate
of infection (Ia) [106], [107]. Therefore, in nutritional
therapy whenver possible preference should be given to
the oral or enteral route [108].
Volume and substrate quantities in
parenteral nutrition of cancer
patients
• Energy expenditure is usually comparable to that of
healthy subjects; only rarely is it necessary to supply
daily energy exceeding 35 kcal per kg body weight (C)
(for children’s intake, cf. chapter “Neonatology/Paedi-
atrics” (http://www.egms.de/en/gms/2009-7/00
0074.shtml)).
• A daily amino acid supply of 1.2 to 1.5 g per kg body
weight is usually appropriate in cancer patients (C) (for
the appropriate dose for children, cf. chapter
“Neonatology/Paediatrics” (http://www.egms.de/en/
gms/2009-7/000074.shtml)).
• There is no agreement on an ideal ratio of lipids and
carbohydrates; the proportion of lipids can be above
35% of the overall energy intakewithout disadvantages
(C).
• Glucose should be the preferred parenteral carbo-
hydrate (B).
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• Micronutrients should be supplied in sufficient
amounts; this should not be less than the iv doses
recommended for healthy persons (C).
• Monitoring of PN should be carried out following the
usual protocol for all PN patients (C).
Commentary
There are generally no accepted standards for the optimal
energy and nutrient intake in oncological patients, par-
ticularly when artificial nutrition is administered exclusive-
ly.
The energy intake should be adapted to the potentially
increased energy requirements and the level of physical
activity. Total energy expenditure of cancer patients was
measured to be comparable to that of healthy subjects,
even though REE was incresed in cancer patients [30].
The cause of this is perhaps an adaptive decrease in
physical activity in metabolically altered cancer patients
[36].
The basis for dosing macro- and micronutrients currently
remains the same as for healthy persons. There is no in-
dication that an intake of protein above the normal dose
(max. 1.5 g protein/kg body weight) has an anticatabolic
effect in oncological patients [109].
Tumour patients show increased lipid oxidation and util-
isation of exogenously administered lipids [58]. Tumour
cells preferentially utilise glucose for their energy require-
ments while healthy tissues display high lipid oxidation
[110]. Therefore, it is recommended to increase the pro-
portion of lipids to over 35% of the total energy supply in
the nutrition of oncological patients [58]. More recent
studies, however, showed that post-absorptive glucose
turnover of malignant tissues is high and does not in-
crease during an intravenous glucose infusion [111];
thus, the theoretical benefit of lipid over glucose solutions
may be clinically irrelevant.
Metabolic and immunological effects of various lipid
solutions (LCT, MCT) have been compared mainly in sur-
gical environments. The postulated benefit of medium-
chained triglycerides (MCT) over long-chained triglycerides
(LCT) could not be established in various clinical studies
[112], [113]. There are no data in cancer patients under-
going radiotherapy or chemotherapy substantiating bene-
fits ofmore recently developed parenteral lipid emulsions,
with increased contents of n-9 or n-3 fatty acids.
Attention should be given to providing a sufficient supply
of micronutrients. The recommendations for intake in
other patient population should be followed (cf. chapter
“Water, electrolytes, vitamins and trace elements” (ht-
tp://www.egms.de/en/gms/2009-7/000080.shtml)).
There are no data supporting a clinical advantage of very
high doses of micronutrients.
Special substrates
• The provision of special substrates such as glutamine,
arginine, taurine, branched-chain amino acids or n-3
fatty acids is not recommended due to lack of convin-
cing data supporting their use (C).
Commentary
Glutamine has been studied as a possible oral supple-
ment to reduce toxic side-effects of radiation or chemo-
therapy [114]. Parenteral glutamine has been used in
haematopoietic stem cell transplantations (HSCT). Find-
ings to date are inconsistent.
In a randomized study of patients after allogeneic HSCT
Ziegler et al. showed a significantly improved nitrogen
balance, reduced infection rate and shorter length of stay
(LOS) for patients supplemented with glutamine (0.57
g/kg/d) compared a control group on an isonitrogenic
and isocaloric diet (Ib) [115]. In a randomized follow-up
study these data, however, could only be repeated with
respect to a reduction in LOS (Ib) [116]. In a later study,
the same working group was not able to document any
advantage of parenteral glutamine (0.57 g/kg/d) in a
similar clinical situation [117] (Ib).
In a further randomised study patients after HSCT receiv-
ing 3–4 weeks of glutamine-enriched PN showed signifi-
cant increases in total lymphocyte counts, T-lymphocytes,
CD4 and CD8 cells, while the clinical outcome was un-
changed [118] (Ib). In a randomised study in patients
after autologous HSCT, high daily doses of intravenous
alanyl-glutamine dipeptide (30 g glutamine) resulted in
increased relapse andmortality rates as well as increased
costs [119] (Ib).
One randomised study, which highlighted the possible
protective role of glutamine infusions on hepatic functions
during HSCT justifies further studies, especially with a
focus on the prevention of veno-occlusive disease [120]
(Ib).
In hematological patients undergoing intensive chemo-
therapy supplementation with glutamine dipeptide had
no effect on hematological parameters or clinical toxicity;
the glutamine group, however, showed significantly more
weight gain during the study period [121].
In a randomised study of patients with acute myeloid
leukaemia requiring PN supplementation with glutamine
(20 g) resulted in a more rapid recovery of neutrophils
after myelosuppressive chemotherapy, but no reduction
in the incidence of neutropenic fever and no improvement
in other immunological parameters [122] (Ib).
According to the current ASPEN guidelines [123], there
is no indication for the administration of pharmacological
doses of glutamine in patients after HSCT. Other recent
recommendations agree with this [124].
There is only scarce evidence concerning other special
substrates; particularly, there are no relevant data on the
parenteral use of n-3 fatty acids.
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Indications for parenteral nutrition
during radiotherapy
• PN should not be used as a general accompaniment
of radiotherapy (B), but PN is indicated if sufficient
enteral intake cannot be achieved (B).
• PN is indicated in chronic severe radiation enteritis
(C).
Commentary
During the last 10 years no prospective randomised
studies have been published on the use of PN as an ac-
companiment to radiotherapy. So far it has not been
demonstrated that routine PN during radiotherapy or ra-
dio-chemotherapy improves prognosis [81], [125], [126].
During radiation treatment, especially when treating head
and neck areas, whenever possible, sufficient enteral
nutrition should be supplied including the use of sip feeds
or enteral tube feeding [109], [125], [127], [128].
PN is indicated if sufficient enteral nutrition is not pos-
sible, e.g. as a result of acute radioation enteritis; if nutri-
tional deficits exist and radiation is intended to cover the
upper gastrointestinal tract such that an intended PEG
would need to be placed within the radiation field; and
during neoadjuvant treatment, if insertion of a PEG sys-
tem is not recommended, e.g. in oesophageal resections
and planned gastric interposition. Chronic radiation en-
teritis develops in approx. 5% of cases subjected to ab-
dominal radiation; this may be accompanied by intestinal
failure, fistulae, perforation or chylous ascites and these
cases frequently require long-term PN [67], [129], [130],
[131], [132].
No benefit of special parenteral substrates such as
glutamine has been established for radiotherapy proced-
ures.
Indications for parenteral nutrition
during chemotherapy
• The indications for PN during chemotherapy are not
different from general indications in malignant dis-
eases. Routine PN therapy as an accompaniment to
chemotherapy is not indicated (B).
Commentary
In 1990 McGeer et al. published a meta-analysis on the
use of PN during chemotherapy (Ia) [133]. They reported
that PN is associated with a trend towards shorter survival
and reduced tumour response. They concluded that
routine PN is not advisable in patients undergoing
chemotherapy. Klein and Koretz analysed 18 randomised
studies with clinically relevant end points on the effect
of PN in patients treated with chemotherapy. They con-
cluded that there were no evident advantages of PN with
regards to overall survival, tumour responses and toxicity
of chemotherapy, but there was an increased rate of in-
fection in those receiving PN (Ib) [81].
It is difficult to draw reliable conclusions from the existing
data due to serious flaws in most study designs, such as
insufficient number of patients treated, inclusion of ex-
tremely inhomogeneous patient groups, large variability
of the nutrient solutions used, large variability of antitu-
mor therapies, and inclusion of patients who were not
suffering from malnutrition as well as patients who
maintained normal oral food intake [81]. Randomised
studies, i.e. by De Cicco et al, which differentiated
between normal and malnourished patients undergoing
chemotherapy, were able to detect an improvement in
the nitrogen balance in severely malnourished patients
while no effect was seen in patients without malnutrition
[134] (Ib).
Recent recommendations by the American Gastroentero-
logical Association (AGA) and the American Society for
Parenteral and Enteral Nutrition (ASPEN) have come to
similar conclusions. The AGA report reviewed 19 random-
ised studies and concluded that PN had no influence on
the survival of patients who were treated with chemother-
apy or radiation treatment, although a positive influence
may be possible after bone marrow transplants. Accom-
panying PN has an unfavourable effect on other param-
eters in patients treated for chemotherapy, radiotherapy
or bone marrow transplants, mainly an increase in infec-
tious complications and a decrease of the response to
chemotherapy (Ib) [85].
The ASPEN recommendations specify that PN as routine
accompaniment of chemotherapy is not justified and
potentially dangerous due to the increased risk of infec-
tion. It is pointed out, however, that PN should be offered
to patients who are malnourished and who are unable to
absorb sufficient nutrients over a long time period [135].
Regarding all published recommendations it is important
to note that all randomised studies on which they are
based were performed more than 10 years ago and that
many are flawed as mentioned above. More recent
studies report fewer complications of long-term PN [67],
[76], [77], [78], [136], [137], suggesting that the benefits
and risks of PN administration during chemotherapy
should be reviewed again in the near future.
Indications for parenteral nutrition
during autologous/allogeneic stem
cell transplantion
• PN is required only in selected patients after autolog-
ous transplantations, while after allogeneic transplant-
ation PN is usually required in most patients and for
prolonged time periods due to the development of
pronouncedmucositis andGvH-related gastrointestinal
damage (C).
• Particular attentionmust be paid to the increased risk
of bleeding and infection associated with PN (C).
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Commentary
In patients after autologous transplantations impaired
food intake is usually of short duration (2–3 weeks). Nu-
tritional problems in allogenic transplant patients usually
are more severe and prolonged. Thus, there is no need
for routine PN after autologous transplantations, but PN
may be necessary if complications develop such as pro-
longed mucositis [138]. After allogenic transplantations,
PN is routinely administered in most transplantation
centres [138]. In 1987 Weisdorf et al. showed that pro-
phylactic standardised PN significantly improved survival
three years after HSCT [106]. The control group received
only minerals and vitamins intravenously until a reduced
nutritional state was detected. Because patients receiving
early PN had a lower relapse rate, it was speculated that
the better overall survival observed might have been
caused by a possible positive effect of PN on transplant
function, resulting e.g. in an increased graft versus leu-
kaemia effect.
Enteral nutrition is not well tolerated in most cases after
complete conditioning regimens [139]; if tolerated, how-
ever, enteral nutrition in patients with a functioning
gastrointestinal tract has effects on nutritional status that
are comparable to those of PN [124], [140] [141] (Ib).
The French Federation of Cancer Centres, as well as the
authors of a review of relevant randomised studies recom-
mend enteral nutrition as the primary approach in non-
myeloablative conditioning, and PN only in cases of
gastrointestinal complications [141]. It has been recom-
mended to initiate PN when oral or enteral food intake
provides less than 50–60% of calculated requirements
[67], [141].
American and French panels on gastroenterology and
nutrition emphasize that all HSCT patients carry a high
nutritional risk and should, therefore, bemonitored regu-
larly for nutritional deficits before and after transplant-
ation [123], [141].
A small randomised study has observed that a high dose
of lipid (lipid:glucose ratio 80:20) after allogenic trans-
plantation lowered the incidence of lethal acute
graft–versus-host disease and hyperglycaemia [142].
This study has yet to be confirmed.
Certin et al. [143] reported that supplying total rather
than partial PN after autologous transplantation resulted
in a delyed rise in thrombocytes. At the same time, there
weremore cases of infection and hyperglycaemia associ-
ated with total PN as compared to partial PN, whilst a
drop in the level of albumin was prevented. The study
was not randomized and patients receiving total PN may
have been more severely ill. The observation, however,
may support the recommendation not to provide total PN
as a standard treatment after autologous transplant-
ations.
In children an autologous blood stem cell transplantation
usually has only a low impact on nutritional status (III)
[144], [145]. Thus, a targeted nutritional therapy should
be based primarily on the above-mentioned criteria (see:
Indication for PN in cancer patients) or be initiated if a
conditioning therapy is chosen, which is associated with
a high risk for severe mucositis.
In allogenic transplantations the criteria for using PN are
usually given, and PN has been shown to have positive
effects on maintaining the body weight [146], [147] (Ib).
Enteral nutrition is possible in many cases and then is as
effective as PN. In a study by Hopman et al., enteral tube
feeding was possible during 60% of the study period, al-
though it could be used as the sole form of nutrition only
in 3 of 12 children [148] (Ib). In a retrospective analysis,
Langdana et al. reported on their positive experiences
and the high patient acceptance rate for a similar concept
with the preferrential use of enteral nutrition [149] (III).
In all cases the risks of enteral tube feeding (aspiration,
bleeding, diarrhoea, sinusitis, intestinal perforation)
should beweighed against the risks of PN (catheter sepsis
and metabolic complications).
In most cases it appears to be sufficient to restrict the
amount of energy provided to be slightly more than the
resting energy expenditure (see: Influence ofmalignancies
on energy expenditure) [150], [151], [152].
There are no generally accepted indications for the use
of glutamine (see Special substrates).
Indications for parenteral nutrition
independent of antitumor therapies
in incurable cancer patients
• If food intake is insufficient survival of patients in ad-
vanced cancer stages may be compromised more by
inadequate nutrition than by the underlying illness (C).
• Long-term PN should be initiated if intestinal absorp-
tion is severely impaired and if allof the following 4
criteria are fulfilled (C):
1. enteral nutrition is insufficient to maintain nutritional
state,
2. the expected survival is more than 4 weeks,
3. PN is expected to stabilise or improve quality of life,
4. the patient explicitely wishes to receive PN.
Commentary
Oncological treatments today may allow patients with in-
curable cancer disease to survive up to a point at which
further survival is significantly affected the nutritional
state [153]. An inadequate oral or enteral intake results
in progressive weight loss and impaired clinical outcome
(see: The nutritional state influences the clinical out-
come). Randomised studies on the value of PN appear
unethical in these situations [87].
Despite a lack of effective antitumor treatment options,
patients with advanced cancers may have a life expect-
ancy of several weeks or months. If the expected survival
exceeds 2 to 3 months (e.g. the period of survival in total
starvation [154], [155], [156]), it can be reasonably as-
sumed that PN will lengthen the survival of a patient who
does not tolerate enteral nutrition [87]. In this situation
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PN, by providing essential nutrition, constitutes a basic
care rather than a medical therapy [87], [157].
Specialised centres providing long-term PN to patients
with advanced cancer disease report a median survival
period of 2–5 months [69], [70], [71], [73], [74], [75],
[76], [77], [78]. This means that a large proportion of
patients cared for in this manner have a longer period of
survival than that assumed for conditions of complete
starvation. Weight stabilisation was successful in a ma-
jority of patients [69], [70], [71].
Quality of life scores are poorer in parenterally nourished
cancer patients than in healthy subjects undergoing PN;
cancer patients are further burdened by accompanying
depressions and opoid requirements [158]. PN, however,
may stabilise parameters determining quality of life [69],
[70], [71]. Orreval et al. reported that the provision of PN
was perceived as a positive alternative to progressive
weight loss by a small group of patients with advanced
tumours and their relatives [79].
Since the benefits of PN can only have an impact when
life expectancy is impaired more by insufficient food in-
take than by the tumour itself, several expert groups
recommend considering PN when the expected survival
is at least 4 weeks [135] or 2–3 months depending on
the tumour [85], [87], [159], [160]. No advantage of PN
should be expected when survival is shorter.
It is extremely difficult to estimate the life expectancy of
a cancer patient and, hence, the possible advantages of
artificial nutrition. These patients should, therefore, be
seen and evaluated cooperatively by their consultant
oncologist, the nutrition specialist and the palliative care
consultant in order to design a treatment plan that is in
agreement with the patients expectations and wishes.
Parenteral nutrition in terminally ill
patients
• No PN is necessary in dying patients (B).
• The occurrence of agitated confusion induced by de-
hydration can be controlled by parenteral infusion of
saline solutions (or the appropriate paediatric solu-
tions, respectively) (B).
Commentary
During the phase of dying the most important aims of
treatment and care are the alleviation of agonising dis-
comfort and the feelings of thirst and hunger. Fluids and
nutrition are part of the basic care; however, the patient
needs to consent to such offers [157]. Most patients do
not feel hungry in the terminal phase of life and only re-
quire minimal quantities of fluid [161]. It is counterpro-
ductive since it may strain the patient severely and thus
it should be avoided at all cost to continue standardised
infusion regimens into the terminal phase without further
consideration [162].
Regulation of fluid balance should be observed closely.
Both dehydration, induced by diuretics or limited drinking,
and hyperhydration caused by infusions can have adverse
affects on a person’s well-being. The “dry mouth” is one
of the main symptoms of the dying [163]. However, thirst
and “dry mouth” do neither correlate with the degree of
hydration [164] nor with the volume of intravenous infu-
sion [165]. Terminal patients appear to receive too much
fluid in general [162], increasing the risks for peripheral
oedema, ascites, pleural effusions and the development
of a pulmonary oedema.
Dehydration can result in drying of the mucous mem-
branes with subsequent injuries and infections [163], it
reduces alertness and promotes the occurrence of rest-
lessness and confusion [166], thus contributing to the
burden of the patients and their relatives [167]. Retro-
spective studies provided evidence that intravenous flids
may reduce neuropsychiatric symptoms like sedation,
hallucinations, myoclonus and agitation [168], [169]. A
randomised trial in dehydrated terminal cancer patients
could show that subjective discomfort was significantly
improved with the infusion of 1000 ml per day as com-
pared to no infusions and only minimal oral fluid intake
of 100 ml per day [170].
Recommendations for terminal care, therefore, emphasize
that fluid intake should always be prescribed on an indi-
vidual basis and should target the prevention of intoler-
able symptoms. Fluid quantities of 1000 ml per day are
recommended in symptomatic dehydration [170], [171];
in children this corresponds to supplying approx. 50% of
the daily fluid requirements.
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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